Evidence map›Paper›PMID 38941509›Full record

ArticleCancer2024

Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials.

Jonathan L Metts, Jamie M Aye, Jacquelyn N Crane, Sapna Oberoi, Frank M Balis, Smita Bhatia, Kira Bona, Bruce Carleton, Roshni Dasgupta, Filemon S Dela Cruz and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Jonathan L MettsSarcoma Department, Moffitt Cancer Center, Tampa, Florida, USA.ORCID https://orcid.org/0000-0003-1068-7857
Jamie M AyeDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Jacquelyn N CraneDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-8227-5694
Sapna OberoiDepartment of Pediatric Hematology/Oncology, Cancer Care Manitoba, Winnipeg, Manitoba, Canada.ORCID https://orcid.org/0000-0002-6071-0042
Frank M BalisDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-8117-6926
Smita BhatiaInstitute for Cancer Outcomes and Survivorship, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID https://orcid.org/0000-0002-7755-5683
Kira BonaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Bruce CarletonDivision of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Roshni DasguptaDivision of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0003-4839-4937
Filemon S Dela CruzDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Katie A GreenzangDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-7591-2245
Jonathan L KaufmanDepartment of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA.
Corinne M LinardicDepartment of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.
Susan K ParsonsInstitute for Clinical Research and Health Policy Studies and Division of Hematology/Oncology, Tufts Medical Center, Boston, Massachusetts, USA.
Mark Robertson-TessiIntegrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Erin R RudzinskiDepartment of Laboratory Medicine and Pathology, Seattle Children's Hospital and University of Washington Medical Center, Seattle, Washington, USA.
Alice SoragniDepartment of Orthopedic Surgery, University of California Los Angeles, Los Angeles, CA, USA.
Elizabeth StewartDepartment of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Brenda J WeigelDivision of Pediatric Hematology Oncology, University of Minnesota, Minneapolis, Minnesota, USA.
Suzanne L WoldenDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Aaron R WeissDepartment of Pediatrics, Maine Medical Center, Portland, Maine, USA.ORCID https://orcid.org/0000-0001-8352-3963
Rajkumar VenkatramaniTexas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
Christine M HeskePediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0003-0956-6249

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
Towards a preventive cancer vaccine for children with constitutional mismatch repair deficiencyUG1CA189955 · NCI · PUBLIC HEALTH INSTITUTE · PI BRAD H POLLOCK, Michael E. Roth · 2014 to 2026
$62.5M
Development and translation of novel therapies for pediatric sarcomaZIABC011774 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HESKE, CHRISTINE · 2017 to 2025
$9.3M
NCI NIH HHS U10 CA180886NCI NIH HHS U10CA180886NCI NIH HHS UG1 CA189955NCI NIH HHS UG1CA189955
6 · The paper itself

Abstract

Clinical trials conducted by the Intergroup Rhabdomyosarcoma (RMS) Study Group and the Children's Oncology Group have been pivotal to establishing current standards for diagnosis and therapy for RMS. Recent advancements in understanding the biology and clinical behavior of RMS have led to more nuanced approaches to diagnosis, risk stratification, and treatment. The complexities introduced by these advancements, coupled with the rarity of RMS, pose challenges to conducting large-scale phase 3 clinical trials to evaluate new treatment strategies for RMS. Given these challenges, systematic planning of future clinical trials in RMS is paramount to address pertinent questions regarding the therapeutic efficacy of drugs, biomarkers of response, treatment-related toxicity, and patient quality of life. Herein, the authors outline the proposed strategic approach of the Children's Oncology Group Soft Tissue Sarcoma Committee to the next generation of RMS clinical trials, focusing on five themes: improved novel agent identification and preclinical to clinical translation, more efficient trial development and implementation, expanded opportunities for knowledge generation during trials, therapeutic toxicity reduction and quality of life, and patient engagement.

Indexed as

Clinical Trials as TopicQuality of LifeRhabdomyosarcomaChildHumansclinical trialsnovel agentspediatricquality of liferhabdomyosarcoma

Identifiers

PMID38941509
PMCPMC11511643

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.